Prostate cancer is the most commonly diagnosed cancer in males in the world and the second leading cause of mortality in males that is attributable to cancer 1 . After it was shown that androgens and androgen receptor (AR) signalling promote prostate cancer progression, androgendeprivation therapy (ADT) has become the main prostate cancer therapy for patients at different stages of disease 2 . However, a considerable fraction of patients receiving such treatments ultimately progress to a more aggressive disease, developing CRPC 2 . The prognosis for patients with CRPC remains poor and the treatment of these patients remains a major unmet medical need [2] [3] [4] [5] [6] [7] [8] . A better understanding of the mechanisms that drive CRPC could identify more effective therapies. Deregulated AR signalling, induced by genomic amplification of the AR locus, AR splice variants and activation of co-regulators of the AR, is considered the major determinant of CRPC 2 . Activation of several AR-alternative signalling pathways also promotes CRPC 9, 10 . However, these mechanisms suggest that cell-autonomous alterations occur in prostate tumour cells and do not take into consideration that these cells are surrounded by a complex tumour microenvironment. The wellestablished dependency of cancer cells on the tumour microenvironment 11 suggests that the non-cancer-cell component of the tumour may control prostate cancer progression, although the contribution of the tumour microenvironment, and in particular of the tumour immune response to the emergence of CRPC, remains unknown 12, 13 . We and others have previously reported that MDSCs are a prominent immune cell subset infiltrating the CRPC microenvironment [14] [15] [16] 17, 19, 20 . MDSCs can support tumorigenesis by either suppressing the antitumour immune response or by promoting angiogenesis and senescence evasion in a number of contexts including prostate cancer 15, 16, 21 . MDSCs have been also found to be increased in patients that do not respond to ADT 20 . However, whether MDSCs support androgen-independent tumour growth and the emergence of CRPC remains unknown. Here, we show that IL-23 secreted by increased numbers of MDSCs in both human and mouse prostate tumours can confer androgen independence in a non-cell autonomous manner through the activation of AR signalling. Inhibition of IL-23 or IL-23 receptor signalling in these tumours restores sensitivity to ADT.
1
. After it was shown that androgens and androgen receptor (AR) signalling promote prostate cancer progression, androgendeprivation therapy (ADT) has become the main prostate cancer therapy for patients at different stages of disease 2 . However, a considerable fraction of patients receiving such treatments ultimately progress to a more aggressive disease, developing CRPC 2 . The prognosis for patients with CRPC remains poor and the treatment of these patients remains a major unmet medical need [2] [3] [4] [5] [6] [7] [8] . A better understanding of the mechanisms that drive CRPC could identify more effective therapies. Deregulated AR signalling, induced by genomic amplification of the AR locus, AR splice variants and activation of co-regulators of the AR, is considered the major determinant of CRPC 2 . Activation of several AR-alternative signalling pathways also promotes CRPC 9, 10 . However, these mechanisms suggest that cell-autonomous alterations occur in prostate tumour cells and do not take into consideration that these cells are surrounded by a complex tumour microenvironment. The wellestablished dependency of cancer cells on the tumour microenvironment 11 suggests that the non-cancer-cell component of the tumour may control prostate cancer progression, although the contribution of the tumour microenvironment, and in particular of the tumour immune response to the emergence of CRPC, remains unknown 12, 13 . We and others have previously reported that MDSCs are a prominent immune cell subset infiltrating the CRPC microenvironment [14] [15] [16] . MDSCs are a heterogeneous population of activated immune cells that are expanded in pathological conditions, including cancer, and that have potent immunosuppressing activity 17 . On the basis of their expression markers, MDSCs can be classified into monocytic MDSCs or polymorphonuclear (PMN)-MDSCs 18 . Higher numbers of circulating and tumour-infiltrating MDSCs have been observed in a large fraction of patients who have different types of tumours including prostate cancer 17, 19, 20 . MDSCs can support tumorigenesis by either suppressing the antitumour immune response or by promoting angiogenesis and senescence evasion in a number of contexts including prostate cancer 15, 16, 21 . MDSCs have been also found to be increased in patients that do not respond to ADT 20 . However, whether MDSCs support androgen-independent tumour growth and the emergence of CRPC remains unknown. Here, we show that IL-23 secreted by increased numbers of MDSCs in both human and mouse prostate tumours can confer androgen independence in a non-cell autonomous manner through the activation of AR signalling. Inhibition of IL-23 or IL-23 receptor signalling in these tumours restores sensitivity to ADT.
MDSCs confer castration resistance
By analysing biopsies from patients with castration-sensitive prostate cancer (CSPC) and CRPC, we found that PMN-MDSCs (CD11b
+ cells) 18 were enriched in CRPC and localized in close proximity to EpCAM + epithelial tumour cells ( Fig. 1a and Extended Data Fig. 1a) . Notably, increased PMN-MDSCs in tumours were not associated with increased levels of CD11b 
CD15
− cells (Extended Data  Fig. 1b) . Therefore, we hypothesized that tumour infiltrating PMNMDSCs could directly contribute to the emergence of CRPC. We investigated this hypothesis using the Pten-null prostate conditional knockout (Pten PC−/− ) mouse model and two additional allograft models of prostate cancer (TRAMP-C1 and MyC-CaP) that develop tumours driven by Pten loss, p53 and RB inactivation, and MYC amplification, respectively 2 . As previously reported 22 , surgical castration of Pten PC−/− mice leads to initial tumour regression (castration-sensitive phase, t = 4 weeks) followed by tumour progression and emergence
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of castration-resistant prostate tumours (castration-resistant phase, t = 12 weeks) ( Fig. 1b and Extended Data Fig. 1c, d ). AR target genes are downregulated in tumours in the castration-sensitive phase and upregulated in the castration-resistant phase in castrated mice compared to sham-operated mice (Fig. 1c) . To assess whether castration affects the recruitment of PMN-MDSCs in these tumours, we measured the frequency of PMN-MDSCs (CD11b 
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CS CR CS CR CS CR *** *** ** ** * * *** ** *** PC−/− mice treated with the CXCR2 antagonist or untreated at the end of the study (12 weeks after CTX). n, qRT-PCR analyses of the indicated genes in the prostate tumours of mice treated as in m. Specific n values of biologically independent mice (b-d, m, n) and independent samples (g-j, l) are shown and data are mean ± s.e.m. b, d, h, i, l, m, Statistical analyses (unpaired two-sided Student's t-test): NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001. b, d, Statistical analyses between all groups and time points (two-sided one-way ANOVA): P < 0.001. c, g, j, n, Statistical analyses (paired twosided Student's t-test): *P < 0.05; **P < 0.01; ***P < 0.001.
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Of note, PMN-MDSCs represented the major subset of immune cells that increased in Pten-null tumours upon castration ( Fig. 1e and Extended Data Fig. 2b, c) . This increase in PMN-MDSCs was validated in TRAMP-C1 and MyC-CaP castrated mice that develop CRPC within 10 days after castration (Extended Data Figs. 1f-i, 2a) . Whereas PMNMDSCs increased in castrated tumours, the frequency of tumourinfiltrating macrophages (TAMs) decreased ( Fig. 1e and Extended Data Fig. 2c ).
To assess whether factors secreted by MDSCs affect AR pathway signalling in prostate cancer cells, we co-cultured two mouse androgendependent prostate cancer cell lines, TRAMP-C1 and MyC-CaP, in the presence of conditioned medium obtained from bone marrow (BM)-derived MDSCs (Fig. 1f and Extended Data Fig. 3a, b) . Notably, the conditioned medium of MDSCs sustained the proliferation and survival of cells cultured under full androgen deprivation (FAD), enhancing the transcription of AR target genes (Fig. 1g-j and Extended Data Fig. 3c-f) . These results were further validated in both androgendependent (LNCaP and VCaP) and androgen-independent (22Rv1 and PC3) human prostate cancer cell lines cultured in the presence of conditioned medium from human BM-MDSCs (Fig. 1k, l and Extended Data Fig. 3g-i) . Taken together, these data demonstrated that MDSCs can regulate, in a paracrine manner, androgen-deprivation sensitivity in prostate tumour cells. We next assessed whether depletion of MDSCs could delay the emergence of CRPC in castrated mice. We therefore treated castrated Pten PC−/− mice, TRAMP-C1 and MyC-CaP allograft mice with AZD5069, a selective CXCR2 antagonist that is under clinical evaluation (Clinical Trial NCT03177187, https://clinicaltrials.gov/ct2/ show/NCT03177187). Treatment with the CXCR2 antagonist strongly reduced the tumour infiltration of PMN-MDSCs in all of the mouse models that were analysed (Extended Data Figs. 3j 4a, e) . Notably, whereas Pten PC−/− castrated mice treated with the CXCR2 antagonist did not progress to CRPC, untreated mice developed CRPC four months after castration as demonstrated by the levels of AR target genes (Fig. 1m, n) . This finding was also confirmed in TRAMP-C1 and MyCCaP allograft mice, in which inhibition of MDSC recruitment in the tumour delayed the emergence of CRPC as shown by decreased tumour size and level of AR target genes in treated mice, resulting in longer survival in mice that were treated with the CXCR2 antagonist (Extended Data Fig. 4a-h ). Of note, treatment with the CXCR2 antagonist did not directly affect cell proliferation and AR activity in mouse prostate tumour cells cultured in vitro in FAD (Extended Data Fig. 3k, l) . To corroborate the role of MDSCs as drivers of CRPC in the human setting, we co-injected human BM-MDSCs with LNCaP cells in NOD/ SCID mice, and assessed tumour growth over time in intact versus castrated hosts. In line with our previous results, the co-injection of LNCaP with human BM-MDSCs conferred resistance to castration (Extended Data Fig. 4i, j) . Taken together, these data indicated that MDSCs are increased in CRPC and can promote proliferation of prostate tumour cells by sustaining AR signalling following androgen deprivation.
IL-23 drives insensitivity to androgen deprivation
To determine which MDSC-secreted factors drive castration resistance, we performed a NanoString nCounter gene expression assay in Pten PC−/− tumours from sham and castrated mice. IL-23 and one of the subunits of IL-23 receptor (IL12Rβ1) were the most upregulated genes in tumours from castrate mice compared to controls (Extended Data  Fig. 5a ). Of note, factors that had previously been linked to the regulation of AR pathway, such as IL-6, were not upregulated in Pten PC−/− tumours after castration 13 (Extended Data Fig. 5a ). In line with this evidence, cytokine profile analysis of conditioned medium from mouse MDSCs showed that IL-23 was the most overexpressed factor produced by these cells (Extended Data Fig. 5b ). Immunofluorescence and flow cytometry analyses further confirmed that tumour-infiltrating MDSCs expressed IL-23 in vivo, with PMN-MDSCs that infiltrated castrationresistant tumours expressing even higher levels of IL-23 compared to treatment-naive tumours (Fig. 2a, b) . Moreover, similar to the results 
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found in mice, PMN-MDSCs that infiltrated tumour biopsies from patients with CRPC expressed IL-23 (Fig. 2d, e and Extended Data Fig. 6a ). In addition, the frequency of IL-23-producing tumourinfiltrating PMN-MDSCs was higher in CRPC biopsies than in CSPC biopsies (Fig. 2e) . Notably, expression of CXCL5, a chemokine that stimulates chemotaxis of myeloid cells through CXCR2 23 , was strongly upregulated in castrated tumours compared to controls (Extended Data  Fig. 5a, c, d ). This, together with the finding that CXCR2 inhibition efficiently decreases the recruitment of MDSCs in castrated mice, indicates that CXCL5 is a major regulator of MDSC recruitment in CRPC.
We next assessed the levels of the IL-23 receptor (IL-23R) in tumours from sham and castrated Pten PC−/− mice, and found that IL-23R levels increased in tumour cells following castration (Fig. 2c) . This was further validated in TRAMP-C1 cells cultured in androgen-deprived conditions in vitro (Extended Data Fig. 5e , f). Furthermore, plasma levels of IL-23 in patients with CRPC were substantially higher than in patients with CSPC ( 
s t-test).
e, h, o, Statistical analyses (paired two-sided Student's t-test): *P < 0.05; **P < 0.01; ***P < 0.001.
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encodes IL-23) and IL23R mRNA levels than treatment-naive patients (Extended Data Fig. 6c, d ) and IL23A mRNA levels were linked to MDSC-associated mRNA levels in biopsies from patients with CRPC (Extended Data Fig. 6e, f) .
In line with this evidence, the primary source of IL-23 in tumours from castrated Pten PC−/− mice was the population of PMN-MDSCs (Extended Data Fig. 6g ). Note that TAMs and epithelial tumour cells were only a small fraction of the total IL-23 + cells in these tumours (Extended Data Fig. 6g ). In keeping with this, IL-23 levels significantly decreased in tumours from castrated Pten PC−/− mice that were depleted of MDSCs (Extended Data Fig. 6h ), whereas the depletion of TAMs by an CSF1R antibody 24 in mice with TRAMP-C1 allografts did not delay the emergence of CRPC. Conversely, the reduction of PMN-MDSCs by a CXCR2 antagonist robustly delayed the emergence of CRPC (Fig. 2h, (Fig. 2j-m) . Of note, deleting IL-23 in BM-MDSCs did not affect the levels of other secreted factors in these cells (Extended Data Fig. 7a ). Indeed, IL23
WT and IL23 KO BM-MDSCs had equal immunosuppressive capabilities (Extended Data Fig. 7b ). These results were further validated in a subset of androgen-dependent organoids that were derived from patient-derived xenografts and LNCaP cells kept in FAD and treated in the presence or absence of human recombinant IL-23 (Fig. 2n) . Taken together, these findings identify IL-23 as an MDSC-secreted factor that can sustain the proliferation and survival of prostate cancer cells as well as the transcription of AR-driven target genes in prostate cancer cells cultured in FAD. 
MDSCs activate the IL-23-RORγ pathway

c). Reconstitution with Il23a
KO bone marrow did not alter the recruitment of MDSCs into the tumours and spleens of reconstituted mice (Extended Data Fig. 9d, e) . Of note, treatment with anti-IL-23 antibodies or genetic inactivation of IL-23R in NOD/SCID/γ (NSG) TRAMP-C1 allografts confirmed these results (Fig. 3i, j) , demonstrating that IL-23 directly promotes resistance to castration in prostate cancer by binding to IL-23R that are present on tumour cells.
IL-23 has been reported to regulate the activation of STAT3-RORγ expression in naive CD4 T cells [25] [26] [27] ; both STAT3 and RORγ can affect AR signalling in prostate cancer 28, 29 . We therefore evaluated whether IL-23 secreted by MDSCs affected the STAT3-RORγ signalling axis in prostate cancer in a non-cell autonomous manner. Inactivation of IL-23 in the myeloid compartment of castrated Pten PC−/− mice significantly decreased overall tumour levels of phosphorylated (p)STAT3 and RORγ in vivo (Fig. 3k-m and Extended Data Fig. 8d) ; this was also the case in the TRAMP-C1 model (Extended Data Fig. 9f-h ). RORγ inhibition in vitro also abrogated the proliferative advantage conferred by conditioned medium from MDSCs or IL-23 treatment in TRAMP-C1 (unpaired two-sided Student's t-test): NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
Article reSeArcH cells kept in FAD, and inhibited the transcription of the full-length form of the AR and its constitutively active splice variant (ARv4) as well as downstream AR target genes (Fig. 3n, o) . Taken together, these data demonstrate that IL-23 released by MDSCs into the tumour microenvironment acts directly on the pSTAT3-RORγ signalling axis to drive the transcription of AR and its splice variant and downstream target genes, thus favouring the proliferation and survival of the prostate cancer cells in androgen-ablation conditions. Fig. 4a ). ENZA is a standard treatment for patients with CRPC after primary ADT 2, 32 . Our preclinical study showed that anti-IL-23 increased the efficacy of ENZA (Fig. 4b, c) ; in mice treated with anti-IL-23 and ENZA, we observed a normalization of prostate glands that were affected by cancer ( Fig. 4b and Extended Data Fig. 10a) , with decreased tumour volume (Fig. 4c ) and proliferation (Extended Data Fig. 10a, b) , whereas in mice that were treated with ENZA, alone the treatment was ineffective. Combined anti-IL-23 and ENZA were associated with a robust inhibition of the AR activity and induction of apoptosis of the tumour cells (Fig. 4e-g ). Taken together, these data demonstrate that anti-IL-23 treatment can reverse resistance to castration in prostate cancer and enhance the efficacy of ENZA.
IL-23 targeting improves the efficacy of ADT
Discussion
Our study has identified IL-23 production by MDSCs as a driver of CRPC and adds novel mechanistic insights on how prostate cancers can become insensitive to androgen deprivation and AR blockade. We also report on a different role for MDSCs in cancer, describing an unexpected function for this immune subset. Previous data demonstrated that MDSCs can support tumorigenesis in many cancers through different mechanisms 15, 17, 18 , with preclinical studies indicating that the inactivation of MDSCs increased immune-checkpoint blockade efficacy in CRPC models 16 . IL-23 has also been previously implicated in cancer progression in the context of a different tumour type as a regulator of the pro-tumour immune response [33] [34] [35] . However, to our knowledge, the discovery described here, that IL-23 produced by MDSCs regulates resistance to castration in prostate cancer by sustaining AR signalling, was previously unknown, and adds novel mechanistic insights on how these immune cells support tumorigenesis. This work also shows that inhibition of IL-23 can reverse ADT resistance in men suffering from advanced prostate cancer (Extended Data Fig. 10c ).
In conclusion, we describe an alternative immunotherapeutic strategy for treating advanced prostate cancer that, unlike most other treatments, is not focused on re-activating the function of cytotoxic T lymphocytes against tumour cells. Immunotherapeutic strategies that reactivate cytotoxic T cells by immune-checkpoint blockade have been, to date, only active against a small subset of prostate cancers that are characterized by DNA-repair defects and higher neoantigen loads with increased infiltration of T lymphocytes 36, 37 . Our results demonstrate, on the other hand, that MDSCs are a major player in the endocrine resistance in prostate cancer and that immunotherapies that target the blockade of either MDSC recruitment into tumour, or the direct inhibition of IL-23 can be effective therapeutic strategies for patients that have these lethal and common diseases. Because anti-IL-23 antibodies have been well-tolerated in clinical trials involving patients with autoimmune diseases 30 , these deserve to be clinically evaluated in men that have lethal prostate cancer. We envision that this immunotherapeutic strategy targeting paracrine IL-23 in combination with established endocrine anticancer treatments is highly likely to improve treatment outcome for this common male cancers.
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Animals. All mice were maintained under specific pathogen-free conditions in the IRB facility and experiments were performed according to national guidelines and regulations. All animal experiments were approved by the local ethics committee (TI13/2015 and TI04/2017). Male C57BL/6, FVB, NSG, NOD/SCID mice 6-8 weeks of age were purchased from Jackson Laboratories (Envigo) and acclimatized for at least a week before experiments. Male C57BL/6 IL-23p19KO (Il23a KO ) mice 27 were provided by F. Sallusto (IRB, Bellinzona) and used at 8 weeks of age. Male Pten PC−/− mice were generated and genotyped as previously described 17 . Female Pten loxP/loxP mice were crossed with male PB cre4 transgenic mice and genotyped for Cre using the following primers: primer 1 (5′-AAAAGTTCCCCTGCTGATGATTTGT-3′) and primer 2 (5′-TGTTTTTGACCAATTAAAGTAGGCTGTG-3′) for PTEN loxP/loxP ; primer 1 (5′-TGATGGACATGTTCAGGGATC-3′) and primer 2 (5′-CAGCCACC AGCTTGCATGA-3′) for PB cre . Surgical castration was performed under anaesthesia with isoflurane. Male Pten PC−/− mice were 9-10 weeks old at the time of castration. Mice were monitored postoperatively for recovery from anaesthesia and checked daily for four days postoperatively. Surgical skin clips were removed on postoperative day 5. Mice undergoing treatment were administered control vehicle or therapeutic doses of the appropriate agents. Any mouse that showed signs of distress or lost more than 15% of their initial weight during treatment was euthanized by CO 2 asphyxiation. At the completion of study, mice were euthanized by CO 2 asphyxiation and tissue was collected for histology, mRNA and protein analysis and single-cell suspensions for flow cytometry. For allograft experiments, 2.5 × 10 6 TRAMP-C1 cells, 2.5 × 10 6 TRAMP-C1 Il23r KO cells or 2 × 10 6 MyC-CaP cells were injected subcutaneously into the flank of male C57BL/6, C57BL/6 or FVB mice, respectively. For xenograft experiments 3 × 10 6 LNCaP cells were suspended with or without 3 × 10 6 human BM-MDSCs in a total volume of 100 μl PBS and Matrigel (1:1) and implanted subcutaneously into the flank of NOD/SCID mice. When tumours were approximately 100 mm ). Breathing and body temperature were monitored (SA Instruments, Inc.) and maintained around 30 breaths per minute and 37 °C, respectively. MRI studies included a Rapid Acquisition with Relaxation Enhancement (RARE) High-Resolution T2-weighted (T2w) sequence with fat suppression acquired in the axial plane (TR = 3,800 ms, TE = 45 ms, FOV = 27 mm × 18 mm, spatial resolution = 0.094 × 0.087 mm 2 per pixel, scan time = 8 min, thickness = 0.70 mm, 26 slices) and in the coronal plane (TR = 3,500 ms, TE = 38 ms, FOV = 33 mm × 33 mm, spatial resolution = 0.129 × 0,129 mm 2 per pixel, scan time = 5 min, thickness = 0.60 mm, 20 slices). Images were analysed using NIH software MIPAV (version 7.4.0). The circumference of the whole prostate was outlined on each RARE T2w axial slice containing identifiable prostate and the number of bounded pixels in each slice was computed and added to yield the prostate volume. Coronal T2w images were used for the accurate identification of the basal and apical limits of the prostate. Differentiation of BM-MDSCs in vitro. Mouse BM-MDSCs were differentiated in vitro as previously described 38 . In brief, bone marrow precursors were flushed from the femurs of C57BL/6 or IL-23p19ko mice with RPMI 1640 medium. The cell pellet was resuspended (one femur in 10 ml) in RPMI 1640 containing 10% heat-inactivated FBS and the cells were cultured in vitro in the presence of 40 ng ml −1 GM-CSF and 40 ng ml −1 IL-6. On day 4, the cells were washed and resuspended with RPMI 1640 containing 10% heat-inactivated charcoal-stripped FBS. The day after the cells were stimulated with PMA and ionomycin and after 4 h the supernatant was collected and stored at −80 °C. Analysis of soluble molecules was conducted with Mouse CytokineMAP B version 1.0 (Rules Based Medicine).
Human BM-MDSCs were differentiated in vitro by seeding 10 6 per ml bone marrow precursors in T25 flasks with RPMI 1640 containing 10% heat-inactivated FBS in the presence of 10 ng ml −1 GM-CSF and 10 ng ml −1 IL-6 for seven days 39 . Complete medium was changed when required. After seven days, the cells were analysed by flow cytometry for CD11b, CD33, CD15, HLA-DR expression and when the CD11b + CD33 + CD15 + HLA-DR − population was higher than 80%, the cells were re-suspended in RPMI 1640 containing 10% heat-inactivated charcoal-stripped FBS and after one day stimulated with PMA and ionomycin for 5 h. The supernatant was then collected and stored at −80 °C. In vitro culture experiments. Prostate cancer cell lines were starved in charcoalstripped FBS medium for 72 h and then cultured with RPMI 1640 containing 10% heat-inactivated FBS (normal medium) or kept in full androgen-deprivation medium (FAD; RPMI 1640 containing 10% heat-inactivated charcoal-stripped FBS plus ENZA 10 μM). Then, the cells were stimulated with or without conditioned medium obtained from activated BM-MDSCs, or recombinant IL-23 (100 ng ml −1 ; R&D Systems), with or without RORγ antibody (5 μM; SR2211, Calbiochem). Then the cells were analysed using the crystal violet assay (after 72 h of culture, fold change over the FAD condition), stained with annexin V and 7AAD (after 72 h of culture) or collected for RNA extraction (after 24 h of culture; fold change over the FAD condition). Analyses of IL23A and IL23R mRNA expression in clinical tumours. CSPC RNA-sequencing data for 550 patients was downloaded from the UCSC Cancer Browser (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/). Metastatic castration resistant prostate cancer (mCRPC) RNA-sequencing data for 122 mCRPC patients was generated as part of the SU2C effort 40 . The paired-end transcriptome sequencing reads were aligned to the human reference genome (GRCh37/hg19) using TopHat2 41 (version 2.1.0). Gene expression, as fragments per kilobase of exon per million fragments mapped (FPKM; normalized measure of gene expression), was calculated using Cufflinks 42 . MDSC marker (CD11b, CD33, CD14 and CD15) positive and negative was defined by the high and low quantiles of RNA expression of each transcript and IL23A and IL23R expression level in each biomarker groups were compared by Student's t-test. In order to compare gene expression level between TCGA and SU2C with minimum experimental bias, we included only genes expressed in both TCGA and SU2C with median expression level (FPKM) >0. The gene expression levels in each sample were quantile-normalized, and IL23A expression levels in CSPC and CRPC were compared using a Student's t-test. Human organoids. Organoids were grown in 3D Matrigel (356231, Corning) under prostate epithelial conditions 43 . Cell viability was measured using 3D CellTiter-Glo 3D reagent (G9681, Promega) by quantifying metabolically active cells releasing ATP. Cell line-derived organoids were plated at a density of 2,000 cells per well in 96-well optical plates (3610, Corning) embedded in Matrigel as hanging drops (5 μl per well). Cells were treated with recombinant IL-23 (300-01A, PeproTech) at 100 ng ml −1 or culture with ENZA (10 μM) with or without recombinant IL-23. Luminescence measurements were performed after seven days in culture. Each IL-23 condition was normalized to its experimental control. Characterization of the immune tumour microenvironment. Tumours were disaggregated and digested in collagenase D and DNase for 30 min at 37 °C to obtain a single-cell suspension. For intracellular cytokine detection, cells were stimulated for 5 h with PMA and ionomycin plus Golgi Plug. After neutralization of unspecific binding with a CD16/CD32 antibody (clone 93), single-cell suspensions were stained with specific monoclonal antibodies (primary antibodies directly conjugated) to assess the phenotype and diluted 1:200. The antibodies used were: CD45 (clone 30-F11, lot no. B235438); Ly-6G (clone 1A8, lot no. B194432); Ly6C (clone HK1.4, lot no. B243043), CD11b (clone M1/70, lot no. B233927); F4/80 (clone BM8, lot no. 4305911), CD206 (clone C068C2, lot no. B230155), CD11c (clone N418, lot no. B226270), B220 (clone RA3-6B2, lot no. B210434), CD3 (clone 145-2C11, lot no. B241616), CD8 (clone 53-6.7, lot no. B193838), CD4 (clone GK1.5, lot no. B240053), NK1.1 (clone PK136, lot no. 4291566), CD90.2 (clone 30-H12, lot no. B190542), PDL1 (clone 10F.9G2, lot no. B191993), EpCAM (clone G8.8, lot no. B230070), pan-cytokeratin (clone C11, Lot. 4528S), IL-17 (clone TC11-18H10.1, lot no. B201753), IL-23p19 (clone FC23CPG, lot no. 4321359), isotype (rat IgG1, kappa, eBRG1) IL-23R (clone 12B2B64, lot no. 4321359). For flow gating, we used isotype controls of fluorescence minus one controls. All the antibodies were purchased from eBioscience or Biolegend. Samples were acquired on a BD Fortessa flow cytometer (BD Biosciences). Data were analysed using FlowJo software (TreeStar). Immunohistochemistry and immunofluorescence of mouse tissues. For immuno histochemistry, tissues were fixed in 10% formalin (5701, ThermoScientific) and embedded in paraffin in accordance with standard procedures. Preceding immuno histochemical staining, tumour sections (4 μm) were exposed to two washes with OTTIX plus solution (X0076, Diapath) and subsequent hydration with OTTIX shaper solution (X0096, Diapath) followed by deionized water. Antigen unmasking was performed by heating sections in the respective pH solutions based on the antibodies used at 98 °C for 20 min. Subsequently the sections were blocked for peroxidases and nonspecific binding of antibodies using 3% H 2 O 2 (23615.248, VWR) and Protein-Block solution (X0909, DAKO Agilent technologies), respectively, for 10 min each, split by 0.5% PBST washing. Haematoxylin and eosin staining was performed according to standard procedures. Sections were stained for anti-Ki-67 (clone SP6; Laboratory Vision Corporation), anti-pSTAT3 (Tyr705; clone D3A7; Cell Signaling). Images were obtained using objectives of 5×, 10× and 40× magnification and pixel images of 2.24 μm, 1.12 μm and 0.28 μm, respectively. All the quantifications were done using the public online software ImmunoRatio (http://153.1.200.58:8080/immunoratio/). For the immunofluorescence staining, tissue paraffin-embedded sections were stained with 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI) (70238421, Roche), anti-IL-23 (ab45420, Abcam), anti-Ly6G (RB6-8C5, GeneTex). Confocal images were obtained with the Leica TCS SP5 confocal microscope using a 10×/1.25 NA oil objective. In vitro T cell suppression assay. In vitro suppression assays were carried out in RPMI with 10% FCS in 96-well U-bottom plates (Corning). Naive splenocytes were labelled with 5 μM CFSE (Molecular Probes) and activated in vitro with anti-CD3 and anti-CD28 beads (Invitrogen) according to the manufacturer's instructions. Conditioned medium from BM-MDSCs was added to the culture. After three days, the proliferation of CFSE-labelled CD8 + T cells was analysed by BD Fortessa. CRISPR-Cas9 transfection. TRAMP-C1 cells were grown in 75-cm 2 flask to 50-60% confluency in DMEM medium supplemented with 10% heat-inactivated FBS, 100 U ml −1 penicillin, 0.1 mg ml −1 streptomycin and 2 mM l-glutamine. The transfection of the Il23r CRISPR-Cas9 KO plasmid (Santa Cruz Biotechnology) was performed using jetPRIME transfection reagent according to the manufacturer's protocol at the 1:2 DNA:jetPRIME ratio. After 24 h of transfection, GFPtransduced cells were sorted to 99% purity and single cells were plated in 96-well plates. At day 7 after sorting, the grown cell clones were moved into 24-well plates for further expansion. The knockdown of the Il23r gene in each cell colony was confirmed by western blot. NanoString. The nCounter analysis system (NanoString Technologies) was used to screen for the expression of signature genes associated with cancer-inflammation pathways. Two specific probes (capture and reporter) for each gene of interest were used. In brief, 5 μl of RNA (the concentration is higher than 25 ng μl −1 ) was hybridized with customized Reporter CodeSet and Capture ProbeSet as Mouse PanCancer Immune Profiling Panel including 700 selected genes (NanoString Technologies) according to the manufacturer's instructions for direct labelling of mRNAs of interest with molecular barcodes without the use of reverse transcription or amplification. Total RNA was quantified by NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilming-ton, DE) and RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). The hybridized samples were then recovered in the NanoString Prep Station and the mRNA molecules were counted with the NanoString nCounter. For expression analysis, each sample profile was normalized to geometric mean of 20 housekeeping genes included in the panel.
Immune tumour microenvironment characterization of tumours from patients with prostate cancer. Tumours were disaggregated and digested in collagenase I and DNase for 20 min at 37 °C to obtain single-cell suspensions. For intracellular cytokine detection, cells were stimulated for 5 h with PMA and ionomycin plus Golgi Plug. Single-cell suspensions were stained with specific monoclonal antibodies diluted 1:200 (primary antibodies directly conjugated) to assess the phenotype. The antibodies used were: CD45RA (clone MEM-56, 1:50), CD33 (clone WM53), CD11b (clone ICRF44), CD15 (clone W6D3), HLA-DR (clone L243), IL-23p19 (clone 23DCDP). For flow gating, we used isotype controls of fluorescence minus one controls. All antibodies were purchased from eBioscience or Biolegend. Immunohistochemistry was performed on 4-μm FFPE tissue sections using an automated staining platform (Bond-RX, Leica Microsystems). Optimal antibody concentrations were determined for primary antibodies against CD15 (M3631, Dako, clone Carb-3, dilution 1:200), CD33 (ab11032, Abcam, clone 6C5/2, dilution 1:100), CD11b (ab52477, Abcam, clone EP1345Y, dilution 1:100) IL-23 (ab190356, Abcam, clone EPR5585(N), dilution 1:100) and EpCAM (2929S, Cell Signaling, clone VU1D9, dilution 1:500). Antibody labelling was detected with the Bond Polymer Refine Detection Kit (DS9800, Leica Microsystems). 3,3-diaminobenzidine tetrahydroxychloride (DAB) was used as chromogen and the slides were counterstained with haematoxylin. Human control samples included colorectal specimens. In each staining batch, positive and negative controls were incubated with and without primary antibody. RNA expression and qPCR. RNA isolation (TRIzol, Qiagen) and retro-transcription with SuperScriptIII (Invitrogen, 11752-250) were performed according to the manufacturer's instructions. qPCR reactions (Bio-Rad) were performed using Article reSeArcH KAPA SYBR FAST qPCR green (KK4605; Applied Biosystems) and the specific primers reported below. Primer sequences were obtained from PrimerBank (http:// pga.mgh.harvard.edu/primerbank/index.html) or Bio-Rad. Each expression value was normalized to HPRT or GADPH level as reference. The primer sequences used were as follows: CXCL1 forward, 5′-CTGGGATTCACCTCAAGAACATC-3′; reverse, 5′-CAGGGTCAAGGCAAGCCTC-3′. CXCL2 forward, 5′-GCGTCACAC TCAAGCTCTG-3′; reverse, 5′-CCAACCACCAGGCTACAGG-3′; CXCL3 forward, 5′-ATCCCCCATGGTTCAGAAA-3′; reverse, 5′-ACCCTGCAGGAAG TGTCAAT-3′; CXCL5 forward, 5′-GTTCCATCTCGCCATTCATGC-3′; reverse, 5′-GCGGCTATGACTGAGGAAGG-3′. GAPDH forward, 5′-AGGT CGGTGTGAACGGATT-3′; reverse, 5′-TGTAGACCATGTAGTTGAG-3′. IL23p19 forward, 5′-CCAGCAGCTCTCTCGGAATC-3′; reverse, 5′-TCATATG TCCCGCTGGTGC-3′. Bio-Rad primers used were: Hprt PrimePCR PreAmp for SYBR Green Assay: Hprt, mouse qMmuCID0005679; Ar PrimePCR PreAmp for SYBR Green Assay: Ar, mouse qMmuCID0005164; Nkx3-1 PrimePCR PreAmp for SYBR Green Assay: Nkx3-1, mouse qMmuCED0046482; Pbsn PrimePCR PreAmp for SYBR Green Assay: Pbsn, mouse qMmuCID0017831; Fkbp5 PrimePCR PreAmp for SYBR Green Assay: Fkbp5, msouse qMmuCID0023283. Western blot analyses and protein detection. Tissue and cell lysates were prepared with RIPA buffer (1× PBS, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail; Roche). The total protein concentration was measured using a BCA Protein Assay Kit (23225; Pierce). Equal amounts of proteins were separated by SDS-PAGE and western blotted onto a 0.45-μm nitrocellulose membrane. Membranes were blocked in 5% defatted milk or 5% BSA in Tris-buffered saline containing 0.1% Tween-20 (TBST), probed with diluted antibodies and incubated at 4 °C overnight. The following primary antibodies were used: rabbit polyclonal anti-HSP90 (1:1,000 dilution, Cell Signaling), rabbit polyclonal anti-pSTAT3 (Tyr705) (1:1,000 dilution, Cell Signaling), rat monoclonal anti-RORγt (5:1,000 dilution, clone AFKJS-9, eBioscence), rabbit polyclonal anti-IL-23R (H-300) (1:1,000 dilution, Santa Cruz). After washing in TBST, the membrane was incubated with secondary antibodies that were conjugated to horseradish peroxidase (HRP) (1:5,000 dilution, Cell Signaling). The protein bands were visualized using the ECL Western Blotting Substrate (Pierce). Supplementary Table 1 ). Four patients with CRPC, enrolled at Azienda Ospedaliera di Padova, and four patients with CSPC, enrolled at IRCCS Ospedale San Raffaele, were selected to perform the immune tumour microenvironment characterization by flow cytometry analyses. Case selection was blinded to baseline characteristics, treatments received, clinical outcome and molecular characterization to reduce any potential selection bias. Finally, plasma from 120 patients with CRPC with sufficient samples stored (including 28 plasma samples within 40 days of CRPC biopsy) and 20 patients with CSPC were analysed for IL-23 levels. Statistical analysis and reproducibility. Data analyses were carried out using GraphPad Prism version 7. The data are mean ± s.e.m., individual values as scatter plots with column bar graphs and were analysed using Student's t-tests (paired or unpaired according to the experimental setting) by a two-sided test, and, when indicated, followed by Wilcoxon signed-rank test. One-way ANOVA was used to compare three or more groups in time point analyses. Differences were considered significant when P < 0.05 and are indicated as not significant, *P < 0.05, **P < 0.01, ***P < 0.001. Non-parametric tests were applied when variables were not normally distributed using the SPSS statistical software. n values represent biological replicates. Survival curves were compared using the log-rank test (Mantel-Cox). Because of evidence of overdispersion, tumour-infiltrating PMN-MDSC (CD15
+ cells were analysed using mixed-effect negative binomial regression model (with per patient random intercept) when comparing paired biopsies, and a negative binomial regression model was used when analysing the association between CRPC biopsies and IL-23. PMN-MDSC (coefficient, 1.49; 95% confidence interval, 0.83-2.15; P < 0.001); CD15
−
CD11b
+ cells (coefficient, 0.43; 95% confidence interval, 0.04-0.83; not significant (P > 0.05)). All statistics and reproducibility information are reported in the figure legends. For animal studies, sample size was defined on the basis of past experience with the models 15 , to detect differences of 20% or greater between the groups (10% significance level and 80% power). For ethical reasons the minimum number of animals necessary to achieve the scientific objectives was used. Animals were allocated randomly to each treatment group. Different treatment groups were processed identically and animals in different treatment groups were exposed to the same environment. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. 
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Abcam, clone EP1345Y) and EpCAM Alexa Fluor® 647 conjugate (#5447S, CellSignaling, clone VU1D9) anti-CD15 (#M3631, Dako, clone Carb-3, dilution 1:200), rabbit monoclonal (IgG) antibody anti-IL23 (#ab190356, Abcam, clone EPR5585(N), dilution 1:100) and mouse monoclonal (IgG1) anti EpCAM antibody (#2929S, CellSignaling, clone VU1D9, dilution 1:500) -Western blot analyses:rabbit polyclonal anti-HSP90 (1:1000 dilution, Cell Signaling), rabbit polyclonal anti-phospho-Stat3 (Tyr705) (1:1000 dilution, Cell Signaling), rat monoclonal anti-RORγt (5:1000 dilution, clone AFKJS-9, eBioscence), rabbit polyclonal anti-IL23R (H-300) (1:1000 dilution, Santa Cruz).
Validation
IHC was performed on 4μm formalin-fixed paraffin embedded (FFPE) tissue sections using an automated staining platform (Bond-RX, Leica Microsystems). Optimal antibody concentrations were determined with primary antibodies against CD15 (#M3631, Dako, clone Carb-3, dilution 1:200), CD33 (#ab11032, Abcam, clone 6C5/2, dilution 1:100), CD11b (#ab52477, Abcam, clone EP1345Y, dilution 1:100) IL23 (#ab190356, Abcam, clone EPR5585 (N), dilution 1:100) and EpCAM (#2929S, CellSignaling, clone VU1D9, dilution 1:500). Antibody labelling was detected with the Bond Polymer Refine Detection Kit (#DS9800, Leica Microsystems). 3,3-diaminobenzidine tetrahydroxychloride (DAB) was used as chromogen and the slides were counterstained with hematoxylin. Human control included colorectal specimens. In each staining batch, positive and negative controls were incubated with and without primary antibody. 
Eukaryotic cell lines
Mycoplasma contamination
All the cell lines were regularly tested for mycoplasma (MycoAlert Mycoplasma Detection kit).
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Animals and other organisms
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